(Q44618833)

4 December 2017

title

Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia (English)

1 reference

4 December 2017

1 reference

1 reference

H. Lode

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

C. Grossman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

S. Choudhri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

D. Haverstock

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

J. McGivern

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

Z. Herman-Gnjidic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

D. Church

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14561021

21 March 2024

publication date

1 October 2003

1 reference

full work available at URL

4 December 2017

http://www.resmedjournal.com/article/S0954611103001665/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14561021

https://api.elsevier.com/content/article/PII:S0954611103001665?httpAccept=text/xml

21 March 2024

1 reference

10.1016/S0954-6111(03)00166-5

DOI

https://api.crossref.org/works/10.1016/S0954-6111(03)00166-5

https://api.elsevier.com/content/article/PII:S0954611103001665?httpAccept=text/plain

21 March 2024

1 reference

10.1016/S0954-6111(03)00166-5

DOI

https://api.crossref.org/works/10.1016/S0954-6111(03)00166-5

21 March 2024

1 reference

4 December 2017

volume

97

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

1134-1142

1 reference

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Trends in infectious diseases mortality in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Severity assessment in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Predicting death in patients hospitalized for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Quality of care, process, and outcomes in elderly patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Early Switch From Intravenous to Oral Antibiotics and Early Hospital Discharge

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Streamlining antimicrobial therapy for lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatmen

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900166-5

7 January 2021

10.1016/S0954-6111(03)00166-5

Identifiers

DOI

1 reference

4 December 2017

1 reference